ReviewDrug safety2019

Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.

Danilo Rocco et al.PubMed ↗Publisher ↗

No numbers read from the abstract.